These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 22240861)

  • 1. Dose-dependent impulse control disorders in piribedil overdose.
    Giugni JC; Tschopp L; Escalante V; Micheli F
    Clin Neuropharmacol; 2012; 35(1):49-50. PubMed ID: 22240861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piribedil and pathological gambling in six parkinsonian patients.
    Micheli FE; Giugni JC; Espinosa ME; Calvo DS; Raina GB
    Arq Neuropsiquiatr; 2015 Feb; 73(2):115-8. PubMed ID: 25742580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
    Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
    Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impulse control disorder and piribedil: report of 5 cases.
    Tschopp L; Salazar Z; Gomez Botello MT; Roca CU; Micheli F
    Clin Neuropharmacol; 2010; 33(1):11-3. PubMed ID: 19959959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience.
    Limotai N; Oyama G; Go C; Bernal O; Ong T; Moum SJ; Bhidayasiri R; Foote KD; Bowers D; Ward H; Okun MS
    Int J Neurosci; 2012 Mar; 122(3):145-53. PubMed ID: 22023411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piribedil-induced sleep attacks in patients without Parkinson disease: a case series.
    Gouraud A; Millaret A; Descotes J; Vial T;
    Clin Neuropharmacol; 2011; 34(3):104-7. PubMed ID: 21586915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease.
    Kimber TE; Thompson PD; Kiley MA
    J Clin Neurosci; 2008 Feb; 15(2):205-8. PubMed ID: 18068992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
    J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Impulse control disorders in Parkinson's disease].
    Joutsa J; Kaasinen V
    Duodecim; 2013; 129(22):2351-8. PubMed ID: 24397147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.
    Weintraub D; Koester J; Potenza MN; Siderowf AD; Stacy M; Voon V; Whetteckey J; Wunderlich GR; Lang AE
    Arch Neurol; 2010 May; 67(5):589-95. PubMed ID: 20457959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic dysregulation syndrome in Parkinson's disease.
    Katzenschlager R
    J Neurol Sci; 2011 Nov; 310(1-2):271-5. PubMed ID: 21868039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study.
    Weintraub D; Sohr M; Potenza MN; Siderowf AD; Stacy M; Voon V; Whetteckey J; Wunderlich GR; Lang AE
    Ann Neurol; 2010 Dec; 68(6):963-8. PubMed ID: 21154480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease.
    Hicks CW; Pandya MM; Itin I; Fernandez HH
    Parkinsonism Relat Disord; 2011 Jun; 17(5):379-81. PubMed ID: 21459656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
    Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term follow-up of Parkinson's disease patients with impulse control disorders.
    Sohtaoğlu M; Demiray DY; Kenangil G; Ozekmekçi S; Erginöz E
    Parkinsonism Relat Disord; 2010 Jun; 16(5):334-7. PubMed ID: 20223696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
    Smith LA; Tel BC; Jackson MJ; Hansard MJ; Braceras R; Bonhomme C; Chezaubernard C; Del Signore S; Rose S; Jenner P
    Mov Disord; 2002 Sep; 17(5):887-901. PubMed ID: 12360537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dopamine dysregulation syndrome in Parkinson's disease and restless legs syndrome].
    Bayard S; Cochen De Cock V; Dauvillers Y
    Geriatr Psychol Neuropsychiatr Vieil; 2011 Jun; 9(2):227-35. PubMed ID: 21690031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piribedil-induced sleep attacks in Parkinson's disease.
    Tan EK
    Fundam Clin Pharmacol; 2003 Feb; 17(1):117-9. PubMed ID: 12588638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients (author's transl)].
    Truelle JL; Chanelet J; Bastard J; Six P; Emile J
    Nouv Presse Med; 1977 Oct; 6(33):2987-90. PubMed ID: 22844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.